Morling Joanne R, Yeoh Su Ern, Kolbach Dinanda N
Centre for Population Health Sciences, University of Edinburgh, Medical Buildings, Teviot Place, Edinburgh, UK, EH8 9AG.
Cochrane Database Syst Rev. 2015 Sep 16(9):CD005626. doi: 10.1002/14651858.CD005626.pub3.
Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. The current standard care for the prevention of PTS following DVT is elastic compression stockings. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). However, it is not known whether rutosides are effective and safe in the prevention of post-thrombotic syndrome. This is an update of the review first published in 2013.
To determine the effectiveness and safety of rutosides for prevention of PTS in patients with DVT, compared to placebo, no intervention, or reference medication.
For this update the Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched September 2015) and the Cochrane Register of Studies (CRS) ((CENTRAL) 2015, Issue 8). Clinical trials databases were searched for details of ongoing and unpublished studies.
We planned to include trials of rutosides versus any alternative (placebo, no intervention, or reference medication) in the prevention of PTS in patients with DVT.
Two review authors independently assessed studies for inclusion and intended to extract information from the trials.
No studies were identified comparing rutosides versus any alternative in the prevention of PTS.
AUTHORS' CONCLUSIONS: As there were no studies identified in this review there is currently insufficient evidence to determine the effectiveness and safety of rutosides for prevention of PTS in patients with DVT. Some studies suggest that rutosides may provide short-term relief of PTS symptoms. However, there is nothing published on their use as a preventative therapy for PTS. High quality randomised controlled trials of rutoside versus any alternative are required to build the evidence base in this area.
血栓形成后综合征（PTS）是深静脉血栓形成（DVT）的一种长期并发症，其特征为患肢疼痛、肿胀及皮肤改变。三分之一的DVT患者会在五年内出现血栓形成后后遗症。目前预防DVT后PTS的标准护理措施是使用弹力袜。芦丁是从七叶树（欧洲七叶树）中提取的一组化合物，七叶树是一种用于治疗慢性静脉功能不全（CVI）中水肿形成的传统草药。然而，尚不清楚芦丁在预防血栓形成后综合征方面是否有效和安全。这是对2013年首次发表的综述的更新。
与安慰剂、无干预措施或对照药物相比，确定芦丁预防DVT患者发生PTS的有效性和安全性。
本次更新中，Cochrane血管组试验检索协调员检索了专业注册库（最后检索时间为2015年9月）和Cochrane研究注册库（CRS）（《Cochrane系统评价数据库》2015年第8期）。检索临床试验数据库以获取正在进行和未发表研究的详细信息。
我们计划纳入比较芦丁与任何其他措施（安慰剂、无干预措施或对照药物）预防DVT患者发生PTS的试验。
两名综述作者独立评估纳入研究，并打算从试验中提取信息。
未检索到比较芦丁与任何其他措施预防PTS的研究。
由于本综述未检索到相关研究，目前尚无足够证据确定芦丁预防DVT患者发生PTS的有效性和安全性。一些研究表明芦丁可能会短期缓解PTS症状。然而，尚无关于其作为PTS预防性治疗方法的报道。需要高质量的芦丁与任何其他措施对比的随机对照试验来建立该领域的证据基础。
